$ALKS News
Last published 1w ago
- 1w agoALKSAlkermes plc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoALKSQ3 2026 Alkermes plc Earnings Conference Call - ALKERMES PLCEarnings Call TranscriptsGreetings, and welcome to the Alkermes Third Quarter 2026 Financial Results Conference Call. My name is Dylan, and I will be your operator for today's call. All participant lines will be placed on mute to prevent backgro
- 1w agoALKSAlkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)Business Wire— Proof-of-Concept Study to Evaluate Effects of Orexin 2 Receptor Agonist on Symptoms of Depression in Adults With and Without Excessive Daytime Sleepiness — Alkermes plc (NASDAQ:ALKS) today announced the initiation
- 3w agoALKSAlkermes to Report Third Quarter Financial Results on November 3, 2026Business WireAlkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company’s third quarter financial results. The webcast
- 4w agoALKSAlkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine ResearchBusiness Wire— Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be Shared in Oral
- 1mo agoALKSAlkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)Business Wire— ALKS 7290 is the First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful Improvements in ADHD Symptoms in Adults — — ALKS 7290 Was Generally Well Tolerated at All Doses Tested in Healthy Volunteers and
- 1mo agoALKSAlkermes Announces Appointment of Anne C. Whitaker to Board of DirectorsBusiness WireAlkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and
- 2mo agoALKSAlkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® ProgramBusiness Wire— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Narcolepsy and Idiopathic Hypersomnia in Addition to Schizophrenia and Bipolar I Disorder
- 2mo agoAMLXALKSTortugas Neuroscience Announces Appointment of Jim Frates to Board of DirectorsBusiness WireTortugas Neuroscience ("Tortugas"), a clinical-stage central nervous system (CNS)-focused biotech company developing medicines with clinically validated mechanisms of action in indications with both substantial
- 2mo agoALKSThe Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1Business Wire– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy – – At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in
- 3mo agoALKSAlkermes plc Reports Second Quarter 2026 Financial ResultsBusiness WireAlkermes plc (NASDAQ:ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company’s investor
- 4mo agoALKSAlkermes to Report Second Quarter Financial Results on July 28, 2026Business WireAlkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company’s second quarter financial results. The webcast player
- 4mo agoALKSAlkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim AnalysisBusiness Wire— First Long-Term Study of an Orexin 2 Receptor Agonist to Demonstrate Sustained Clinically Meaningful Improvements in Wakefulness and Excessive Daytime Sleepiness for Up to Nine Months in Narcolepsy Type 1 and Type 2
- 4mo agoALKSAlkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026Business Wire— First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to Placebo in
- 4mo agoALKSAlkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and EuropeBusiness WireAlkermes plc (NASDAQ:ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2
- 5mo agoALKSGoldman Sachs 47th Annual Global Healthcare Conference - ALKERMES PLCEarnings Call TranscriptsGood morning, everyone. Thanks for joining us here on the third day of the Goldman Sachs Global Healthcare Conference. And thanks to everyone who joined us here as well as online. And we're thrilled to be joined today by
- 5mo agoALKSAlkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine ResearchBusiness Wire— 26 Abstracts Accepted Demonstrate Alkermes' Commitment to Advancing Understanding and Treatment of Narcolepsy and Idiopathic Hypersomnia — — Detailed Positive Results from Vibrance-2 Phase 2 Study of Alixorexton, an
- 5mo agoALKSAlkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness WireAlkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET (3:00 p.m. BST).
- 5mo agoALKSAlkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual MeetingBusiness Wire— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders — Alkermes plc (NASDAQ:ALKS) today announced plans to
- 5mo agoALKSAlkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific ConferencesBusiness Wire– Real-World Evidence of Positive Impact of LYBALVI® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse Among Patients with Schizophrenia or Bipolar I Disorder, Including Young Adults – – APA
- 6mo agoALKSAlkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic HypersomniaBusiness Wire– LUMRYZ Met All Primary and Key Secondary Endpoints Demonstrating Statistically Significant and Clinically Meaningful Improvements Compared to Placebo in Excessive Daytime Sleepiness and Patient-Reported Disease
- 6mo agoALKSAlkermes plc Reports First Quarter 2026 Financial ResultsBusiness WireAlkermes plc (NASDAQ:ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press release and
- 6mo agoALKSAlkermes to Report First Quarter Financial Results on May 5, 2026Business WireAlkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company's first quarter financial results. The webcast player and
- 6mo agoALKSAlkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual MeetingBusiness Wire— Alixorexton Data From Seven-Week Open-Label Extension Period Demonstrated Sustained Improvements in Patient-Reported Disease Severity, Cognitive Functioning and Fatigue— — Alixorexton Was Generally Well Tolerated at
- 7mo agoALKSFindings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical PsychiatryBusiness Wire— 56-Week Post Hoc Analysis Demonstrated Sustained Reduction in Hard-to-Treat Negative Symptoms — Alkermes plc (NASDAQ:ALKS) today announced the publication of a 56-week post hoc analysis of the effects of
- 7mo agoALKSAlkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2Business WireAlkermes plc (NASDAQ:ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and
- 8mo agoALKSAlkermes Announces Inaugural Alkermes Pathways APN Research Awards™ ProgramBusiness Wire— Competitive Grant Program to Offer Individual Grants of Up to $10,000 per Project — — Inaugural Application Cycle Open to Licensed Psychiatric-Mental Health Nurse Practitioners Across Multiple Clinical Settings
- 8mo agoALKSAlkermes to Present at the Stifel 2026 Virtual CNS ForumBusiness WireAlkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:30 a.m. ET (12:30 p.m. GMT). The live webcast may be
- 8mo agoALKSAlkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026Business WireAlkermes plc (NASDAQ:ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings
- 8mo agoALKSAlkermes plc Announces CEO Succession PlanBusiness Wire— Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes' Current Executive Vice President, Chief
- 8mo agoALKSAlkermes to Present at the TD Cowen 46th Annual Health Care ConferenceBusiness WireAlkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 a.m. ET (2:10 p.m. GMT). The live
- 9mo agoALKSAVDLAlkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine MarketBusiness Wire— Augments Alkermes' Revenue Growth Profile and Diversifies Commercial Portfolio with New High Potential Growth Product, LUMRYZ® (Sodium Oxybate) for Extended-Release Oral Suspension — — Expected to be Accretive
- 9mo agoALKSAlkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026Business WireAlkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company's fourth quarter and year-end 2025 financial results.
- 10mo agoALKSAlixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1Business WireAlkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), based on phase 1 and
- 10mo agoALKSAlkermes to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireAlkermes plc (NASDAQ:ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take
- 10mo agoALKSApproval of Vivitrol, Nda #021897 (Labeling)FDA Approved DrugsApproval Date: 12/22/2025; Drug Name: Vivitrol, Nda #021897; Active Ingredients: NALTREXONE; Company: Alkermes; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021897
- 11mo agoALKSAVDLAnnouncement relating to despatch of Rule 15 proposalGlobeNewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN
- 11mo agoALKSAlkermes to Participate in Two Upcoming Investor ConferencesBusiness WireAlkermes plc (NASDAQ:ALKS) announced today that management will participate in two upcoming investor conferences. 8th Annual Evercore Healthcare Conference Date/Time: Wednesday, Dec. 3, 2025 at 2:10 p.m. ET (7:10 p.m.
- 11mo agoALKSAVDLAlkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plcPR NewswireAlkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have reached...
- 11mo agoALKSAVDLAvadel Board of Directors Declares Lundbeck Proposal a "Company Superior Proposal"GlobeNewswireTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION
- 12mo agoALKSAlkermes Response to Avadel AnnouncementPR NewswireAlkermes plc ("Alkermes") (Nasdaq: ALKS) notes the announcement made by Avadel Pharmaceuticals plc ("Avadel") regarding a possible offer by H....
- 12mo agoALKSAlkermes Response to Avadel AnnouncementPR NewswireAlkermes plc ("Alkermes") (Nasdaq: ALKS) notes the announcement made by Avadel Pharmaceuticals plc ("Avadel") regarding a possible offer by H....
- 12mo agoALKSAVDLAvadel Receives Unsolicited Proposal from LundbeckGlobeNewswireTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION
- 12mo agoALKSAlkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2PR NewswireAlkermes plc (Nasdaq: ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton in...
- 12mo agoALKSAlkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2PR NewswireAlkermes plc (Nasdaq: ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton in...
- 1y agoALKSAlkermes to Participate in Two Upcoming Investor ConferencesPR NewswireAlkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2025 Healthcare Conference...
- 1y agoALKSFORM 8.1(a) & (b) (Opening Position Disclosure)PR NewswireAlkermes plc (Nasdaq: ALKS): IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997,...
- 1y agoALKSAlkermes plc Reports Third Quarter 2025 Financial ResultsPR NewswireAlkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving ...
- 1y agoALKSAVDLAlkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plcPR NewswireAlkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have entered...
- 1y agoALKSAlkermes to Report Third Quarter Financial Results on October 28, 2025PR NewswireAlkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Tuesday, Oct. 28, 2025 to...